載入...
Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...
Na minha lista:
| 發表在: | Circ Rep |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
The Japanese Circulation Society
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7819654/ https://ncbi.nlm.nih.gov/pubmed/33693263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0062 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|